244 related articles for article (PubMed ID: 10537964)
1. Clinical and economic outcomes of olanzapine compared with haloperidol for schizophrenia. Results from a randomised clinical trial.
Hamilton SH; Revicki DA; Edgell ET; Genduso LA; Tollefson G
Pharmacoeconomics; 1999 May; 15(5):469-80. PubMed ID: 10537964
[TBL] [Abstract][Full Text] [Related]
2. [Economic comparison of olanzapine versus haloperidol in treatment of schizophrenia in France].
Le Pen C; Lilliu H; Allicar MP; Olivier V; Gregor KJ
Encephale; 1999; 25(4):281-6. PubMed ID: 10546082
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia: a randomized controlled trial.
Rosenheck R; Perlick D; Bingham S; Liu-Mares W; Collins J; Warren S; Leslie D; Allan E; Campbell EC; Caroff S; Corwin J; Davis L; Douyon R; Dunn L; Evans D; Frecska E; Grabowski J; Graeber D; Herz L; Kwon K; Lawson W; Mena F; Sheikh J; Smelson D; Smith-Gamble V;
JAMA; 2003 Nov; 290(20):2693-702. PubMed ID: 14645311
[TBL] [Abstract][Full Text] [Related]
4. Olanzapine: an updated review of its use in the management of schizophrenia.
Bhana N; Foster RH; Olney R; Plosker GL
Drugs; 2001; 61(1):111-61. PubMed ID: 11217867
[TBL] [Abstract][Full Text] [Related]
5. Olanzapine versus risperidone. A prospective comparison of clinical and economic outcomes in schizophrenia.
Edgell ET; Andersen SW; Johnstone BM; Dulisse B; Revicki D; Breier A
Pharmacoeconomics; 2000 Dec; 18(6):567-79. PubMed ID: 11227395
[TBL] [Abstract][Full Text] [Related]
6. Olanzapine. A pharmacoeconomic review of its use in schizophrenia.
Foster RH; Goa KL
Pharmacoeconomics; 1999 Jun; 15(6):611-40. PubMed ID: 10538333
[TBL] [Abstract][Full Text] [Related]
7. Pharmacoeconomic evaluation of antipsychotic therapy for schizophrenia.
Glazer WM; Johnstone BM
J Clin Psychiatry; 1997; 58 Suppl 10():50-4. PubMed ID: 9265917
[TBL] [Abstract][Full Text] [Related]
8. Cost analysis of the treatment of schizophrenia in the UK. A simulation model comparing olanzapine, risperidone and haloperidol.
Almond S; O'Donnell O
Pharmacoeconomics; 2000 Apr; 17(4):383-9. PubMed ID: 10947493
[TBL] [Abstract][Full Text] [Related]
9. Olanzapine versus haloperidol in the treatment of schizophrenia and other psychotic disorders: quality of life and clinical outcomes of a randomized clinical trial.
Revicki DA; Genduso LA; Hamilton SH; Ganoczy D; Beasley CM
Qual Life Res; 1999 Aug; 8(5):417-26. PubMed ID: 10474283
[TBL] [Abstract][Full Text] [Related]
10. Functional outcomes in schizophrenia: a comparison of olanzapine and haloperidol in a European sample.
Hamilton SH; Edgell ET; Revicki DA; Breier A
Int Clin Psychopharmacol; 2000 Sep; 15(5):245-55. PubMed ID: 10993126
[TBL] [Abstract][Full Text] [Related]
11. A cost-effectiveness clinical decision analysis model for schizophrenia.
Palmer CS; Revicki DA; Genduso LA; Hamilton SH; Brown RE
Am J Manag Care; 1998 Mar; 4(3):345-55. PubMed ID: 10178497
[TBL] [Abstract][Full Text] [Related]
12. Effective resolution with olanzapine of acute presentation of behavioral agitation and positive psychotic symptoms in schizophrenia.
Kinon BJ; Roychowdhury SM; Milton DR; Hill AL
J Clin Psychiatry; 2001; 62 Suppl 2():17-21. PubMed ID: 11232746
[TBL] [Abstract][Full Text] [Related]
13. Superior efficacy of olanzapine over haloperidol: analysis of patients with schizophrenia from a multicenter international trial.
Gomez JC; Crawford AM
J Clin Psychiatry; 2001; 62 Suppl 2():6-11. PubMed ID: 11232753
[TBL] [Abstract][Full Text] [Related]
14. A comparison of the efficacy and safety of olanzapine versus haloperidol during transition from intramuscular to oral therapy.
Wright P; Meehan K; Birkett M; Lindborg SR; Taylor CC; Morris P; Breier A
Clin Ther; 2003 May; 25(5):1420-8. PubMed ID: 12867218
[TBL] [Abstract][Full Text] [Related]
15. [Cost effectiveness analysis of olanzapine versus haloperidol in the treatment of schizophrenia++ in Spain].
Sacristán JA; Gómez JC; Salvador-Carulla L
Actas Luso Esp Neurol Psiquiatr Cienc Afines; 1997; 25(4):225-34. PubMed ID: 9412161
[TBL] [Abstract][Full Text] [Related]
16. Olanzapine vs risperidone in the management of schizophrenia: a randomized double-blind trial in Australia and New Zealand.
Gureje O; Miles W; Keks N; Grainger D; Lambert T; McGrath J; Tran P; Catts S; Fraser A; Hustig H; Andersen S; Crawford AM
Schizophr Res; 2003 Jun; 61(2-3):303-14. PubMed ID: 12729882
[TBL] [Abstract][Full Text] [Related]
17. Olanzapine versus haloperidol treatment in first-episode psychosis.
Sanger TM; Lieberman JA; Tohen M; Grundy S; Beasley C; Tollefson GD
Am J Psychiatry; 1999 Jan; 156(1):79-87. PubMed ID: 9892301
[TBL] [Abstract][Full Text] [Related]
18. Changes in perceived health and functioning as a cost-effectiveness measure for olanzapine versus haloperidol treatment of schizophrenia.
Tunis SL; Johnstone BM; Gibson PJ; Loosbrock DL; Dulisse BK
J Clin Psychiatry; 1999; 60 Suppl 19():38-45; discussion 46. PubMed ID: 10507279
[TBL] [Abstract][Full Text] [Related]
19. Olanzapine versus placebo and haloperidol: quality of life and efficacy results of the North American double-blind trial.
Hamilton SH; Revicki DA; Genduso LA; Beasley CM
Neuropsychopharmacology; 1998 Jan; 18(1):41-9. PubMed ID: 9408917
[TBL] [Abstract][Full Text] [Related]
20. Negative symptoms: a path analytic approach to a double-blind, placebo- and haloperidol-controlled clinical trial with olanzapine.
Tollefson GD; Sanger TM
Am J Psychiatry; 1997 Apr; 154(4):466-74. PubMed ID: 9090332
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
